Speedel public offer
Before attempting to access this website, please read this notice carefully: it applies to all persons who access this website and may affect your rights to access the information contained on this website. Please note that the disclaimer set out below may be altered or updated. You should read it in full each time you visit this website.
In order to view documents on this website, you are required confirm that you have read this notice and agree to be bound by all of its terms; otherwise you will not be able to view the documents on this website. If you are not permitted to view this website, or viewing would result in a breach of the above, or you are in any doubt as to whether you are permitted to view this communication, please exit this website.
Disclaimer
The communication on this website does not constitute an offer to sell or to purchase securities, nor a solicitation of an offer to sell or to purchase securities, whether in the context of the public tender offer in Switzerland by Novartis Pharma AG ("Novartis Pharma") for the shares of Speedel Holding AG ("Speedel") with a nominal value of CHF 2 each (the "Tender Offer") or in any jurisdiction where such offer, solicitation, sale or the acceptance of such offer may be unlawful. It does also not constitute a recommendation to sell or buy shares in Novartis AG or Speedel.
The Offer Prospectus (the "Offer Prospectus") contains the terms and conditions of the Tender Offer, including the scope of the Offer, the way the Tender Offer can be accepted and the restrictions applicable to the Tender Offer in some countries. The Tender Offer is subject to all the terms and conditions set forth in the Offer Prospectus.
The Tender Offer made to the shareholders of Speedel and the Offer Prospectus which has been filed with the Swiss Takeover Board and published in electrionic media and in Le Temps and Neue Zürcher Zeitung in Switzerland on August 11, 2008 have been exclusively prepared under Swiss law and are subject to review and supervision by Swiss authorities only. The Tender Offer is not subject to any formality, registration or approval outside Switzerland. The Tender Offer will not be made and may not be accepted in any jurisdiction where it breaches applicable law or where the applicable law requires Novartis Pharma in any way to change the Tender Offer, to submit an additional application to any authorities or other institutions, or to take any additional actions in connection with the Tender Offer. Novartis Pharma shall not accept and shall have no obligation to accept any tenders made in connection with the Tender Offer from any such jurisdiction. It is not intended to extend the Tender Offer to any such jurisdictions. Documents related to the Tender Offer may neither be distributed in nor sent into such jurisdictions. Such documents do not constitute and may not be used to solicit an offer to sell or to purchase securities by any persons in such jurisdictions. Persons in possession of the Offer Prospectus or any other document relating to the Tender Offer are required to obtain information about any local restriction that may apply and comply therewith. Novartis Pharma and Novartis AG disclaims any liability for any violation of any applicable restrictions by any person.
U.S. Restrictons
Unless otherwise determined by Novartis Pharma, the public offer is not being and will not be made, directly or indirectly, in or into, or by use of mails or any means or instrumentality (including, without limitation, facsimile transmission, telephone and Internet) of interstate or foreign commerce of, or any facilities of a national securities exchange of, the United States of America, and the public offer will not be capable of acceptance by any such use, means, instrumentality or facilities or from within the United States. Accordingly, copies of this public offer are not being, and must not be, mailed or otherwise forwarded, distributed or sent in, into or from the United States, and persons receiving this public offer (including custodians, nominees and trustees) must not mail or otherwise forward, distribute or send it into or from the United States. Doing so may render invalid any purported acceptance.
I hereby confirm that I have read this notice and the restrictions contained therein and agree to be bound by all of its terms. |
|
|
|
Select the country in which you are physically present: |
|
|
|
Corporate publications
